A Comprehensive Evaluation of the Application of the Halcyon(2.0) IMRT Technique in Long-Course Radiotherapy for Rectal Cancer

Abstract

Objective: To evaluate if the Halcyon(2.0) Intensity Modulation Radiotherapy (IMRT) technique has an advantage in the long-course rectal cancer radiotherapy. Methods: A total of 20 clinical IMRT plans of Halcyon(2.0) for long-course (2Gy in 25 fractions) rectal cancer radiotherapy were randomly selected. Based on the parameters of these plans, 20 TrueBeam (with the Millennium 120 MLC) plans were redesigned, respectively. The dosimetry indexes, field complexity parameters, the Gamma Passing Rates (GPR), and the delivery time of the 2 groups of plans were obtained as measures of the plan quality, the modulation complexity, the delivery accuracy, and the delivery efficiency. The differences between the 2 groups of parameters were analyzed, with P < .05 means statistically significant. Results: In terms of dosimetry, there was no significant or clinical difference between the 2 groups in critical dosimetry parameters. The Monitor Unit of the Halcyon(2.0) fields is lower than the TrueBeam fields by 26.39, while the modulation complexity score (MCS), the mean aperture area variability (AAV), and the mean leaf sequence variability (LSV) of the Halcyon(2.0) fields were 23.8%, 20%, and 2.3% larger than those of the TrueBeam fields, respectively. Neither the ArcCheck-based GPRs nor the portal-dosimetry-based GPRs in both 3%/3 mm and 2%/2 mm criteria showed the difference between the Halcyon(2.0) fields and the TrueBeam fields. The Pearson correlation coefficient between GPR(2%/2 mm) and MCS of the Halcyon(2.0) fields was 0.335, while that of the TrueBeam fields was 0.502. The mean total delivery time of the TrueBeam plans was 195.55 ± 22.86 s, while that of Halcyon(2.0) was 124.25 ± 10.42 s ( P < .001), which was reduced approximatively by 36%. Conclusion: For long-course rectal cancer radiotherapy, the Halcyon(2.0) IMRT plans behave almost the same in dosimetry and delivery accuracy as the TrueBeam plans. However, the lower MU and the field modulation complexity, combined with the higher delivery efficiency, make Halcyon(2.0) a feasible and reliable platform in long-course radiotherapy for the rectal cancer.